Dr Dania Daye discusses the need for standardized reporting in AI studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in AI studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Kyle S. Stumetz, DO, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, DO, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Dr Jason Levy discusses the clinical considerations, procedural techniques, and the ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Jason Levy discusses the clinical considerations, procedural techniques, and the ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Heather McArthur speaks about her work examining the impact of perioperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Dr Heather McArthur speaks about her work examining the impact of perioperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Ahead of SIR 2025, Dr Setayesh Sotoudehnia of Mayo Clinic Rochester speaks about her research on MR-guided procedures, her GCAW Award, and the advancement of women in the field of interventional radiology.
Ahead of SIR 2025, Dr Setayesh Sotoudehnia of Mayo Clinic Rochester speaks about her research on MR-guided procedures, her GCAW Award, and the advancement of women in the field of interventional radiology.
In this video from ISET2025, interventional radiologist Dr Nainesh Parikh discusses his presentation on the benefits of prostatic artery embolization in the treatment of prostate cancer.
In this video from ISET2025, interventional radiologist Dr Nainesh Parikh discusses his presentation on the benefits of prostatic artery embolization in the treatment of prostate cancer.
In this video, Dr Walker comments on "Temporary Occlusion Embolectomy: A Cost-Effective Approach to Distal Embolic Protection in Peripheral Artery Disease.”
In this video, Dr Walker comments on "Temporary Occlusion Embolectomy: A Cost-Effective Approach to Distal Embolic Protection in Peripheral Artery Disease.”
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
From redefining what “no-option” truly means, to understanding the role of small artery disease and medial arterial calcification in decision-making, this discussion highlights both clinical data and real-world experience with LimFlow.
From redefining what “no-option” truly means, to understanding the role of small artery disease and medial arterial calcification in decision-making, this discussion highlights both clinical data and real-world experience with LimFlow.
Dr KJ Nagarsheth, Professor of Surgery, Division of Vascular Surgery, at the University of Maryland School of Medicine, offers a concise, real-world readout on the clinical and procedural value of the Artix thrombectomy system.
Dr KJ Nagarsheth, Professor of Surgery, Division of Vascular Surgery, at the University of Maryland School of Medicine, offers a concise, real-world readout on the clinical and procedural value of the Artix thrombectomy system.
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
Bruno C. Odisio, MD, PhD, FSIR, FCIRSE; Iwan Paolucci, PhD
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
Bruno C. Odisio, MD, PhD, FSIR, FCIRSE; Iwan Paolucci, PhD
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ -- Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration...
BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ -- Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration...
SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third...
SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third...
BEDFORD, Mass., March 11, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration...
BEDFORD, Mass., March 11, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration...
Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System.
Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
Updated ischemic stroke recommendations from the American Stroke Association highlight how rapid diagnosis and imaging, extended time windows for stroke treatments and coordinated care involving emergency services, hospitals and health care...
Updated ischemic stroke recommendations from the American Stroke Association highlight how rapid diagnosis and imaging, extended time windows for stroke treatments and coordinated care involving emergency services, hospitals and health care...
BIRMINGHAM, Ala. — February 12, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced that Rob Williamson has been appointed Chief Revenue Officer (CRO), efective March...
BIRMINGHAM, Ala. — February 12, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced that Rob Williamson has been appointed Chief Revenue Officer (CRO), efective March...
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
BIRMINGHAM, Ala. — February 4, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the appointment of Gerhard (Gary) F. Burbach as Chairman of its Board of...
BIRMINGHAM, Ala. — February 4, 2026 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the appointment of Gerhard (Gary) F. Burbach as Chairman of its Board of...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio
LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio
LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
